With the rapid development of deep learning in the text domain, text classification software is commonly used. However, DNN (Deep Neural Network) based text classification software is easily misled by interfering information such as noisy text. It is important to test the text classification software to evaluate its robustness. Existing test methods have limitations, low test success rate, poor quality, high count of queries, etc. To address these issues, we propose a test case generation method based on the Improved Simulated Annealing Algorithm (ISA), which generates test cases through word substitution. ISA utilizes a hierarchical attention network model to evaluate word importance to identify words for substitution. And it uses an optimized BERT model to generate candidate words. During the search process for the optimal test cases, the word substitution rate and semantic perplexity are incorporated into the objective function for searching test cases with good quality, while introducing an adaptive cooling function to shorten generation time. Experimental results show that the test cases generated by ISA can achieve an average test success rate of 94.7%. Compared to the baseline method, the average word substitution rate decreased by at least 15.7%, and the method has a relatively low time cost.

Macro placement, which involves optimizing the positions of modules, is a critical phase in modern integrated circuit design and significantly influences chip performance. The growing complexity of integrated circuits demands increasingly sophisticated placement solutions. Existing approaches have evolved along two primary paths (e.g., constructive and adjustment methods), but they face significant practical limitations that affect real-world chip design. Recent hybrid frameworks such as WireMask-EA have attempted to combine these strategies, but significant technical barriers still remain, including the computational overhead from separated layout adjustment and reconstruction that often require complete layout rebuilding, the inefficient exploration of design spaces due to random mutation operations, and the computational complexity of mask-based construction methods that limit scalability. To overcome these limitations, we introduce EGPlace, a novel evolutionary optimization framework that combines guided mutation strategies with efficient layout reconstruction. EGPlace introduces two key innovations: a greedy repositioning-guided mutation operator that systematically identifies and optimizes critical layout regions, and an efficient mask computation algorithm that accelerates layout evaluation. Our extensive evaluation using ISPD2005 and Ariane RISC-V CPU benchmarks demonstrate that EGPlace reduces wirelength by \textbf{10.8\%} and \textbf{9.3\%} compared to WireMask-EA and the state-of-the-art reinforcement learning-based constructive method EfficientPlace, respectively, while achieving speedups of 7.8$\times$ and 2.8$\times$ over these methods.

Lead optimization, aimed at improving binding affinity or other properties of hit compounds, is a crucial task in drug discovery. Though deep learning-based 3D generative models showed promise in enhancing the efficiency of de novo drug design recently, less research and attention has garnered for structure-based lead optimization. Herein, we propose a 3D pocket-aware diffusion model named Diffleop, which explicitly incorporates the knowledge of protein-ligand binding affinity and information on covalent bonds to guide the denoising sampling process for lead optimization with enhanced binding affinity and rational properties. Specifically, the bond constraint is achieved through diffusion on fully connected molecular graphs, and the determination of atom positions, atom and bond types in each sampling step is guided by the gradient of the binding affinity that is predicted through fitting with an E(3)-equivariant expert network. The comprehensive evaluations indicated that Diffleop outperforms baseline models on lead optimization with higher affinity and more binding interactions, and can generate more drug-like molecules with more rational structures. Diffleop was further applied to optimize 5-methyl-1H-imidazole, our newly discovered lead compound targeting human glutaminyl cyclases (QCs). Three synthesized compounds exhibit substantially improved inhibitory activities against QCs, with the most effective one showing an IC50 value of 8 nM and 3.5-fold better than clinical candidate PQ912.